

**124.201A Cannabidiol investigational product — rules.**

1. If a cannabidiol investigational product approved as a prescription drug medication by the United States food and drug administration is eliminated from or revised in the federal schedule of controlled substances by the federal drug enforcement agency and notice of the elimination or revision is given to the board, the board shall similarly eliminate or revise the prescription drug medication in the schedule of controlled substances under [this chapter](#). Such action by the board shall be immediately effective upon the date of publication of the final regulation containing the elimination or revision in the federal register.

2. The board shall adopt rules pursuant to [chapter 17A](#) to administer [this section](#). The board may adopt rules on an emergency basis as provided in [section 17A.4, subsection 3](#), and [section 17A.5, subsection 2](#), to administer [this section](#), and the rules shall be effective immediately upon filing unless a later date is specified in the rules. Any emergency rules adopted in accordance with [this section](#) shall also be published as a notice of intended action as provided in [section 17A.4, subsection 1](#).

[2017 Acts, ch 162, §1, 25](#)

NEW section